NCT07155694Not yet recruitingPhase 4
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone or combination therapy. Secondary Objectives: (1). Correlate changes in exosome-based PSP with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. (2) with systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12), hs-CRP and (3) arterial stiffness measures and with (4) APOL1 mRNA expression levels in peripheral blood derived mononuclear cells (MNC).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 13 Aug 2025
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Washington D.C. Veterans Affairs Medical Center
- Diseases
- Chronic kidney disease
- NCT number
- NCT07155694
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From 1 Oct 2026 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active skin wounds undergoing treatment or recent surgery within 1 month (due to possible aberrations in glycemic control)
- Planned surgery or planned hospital admission within 5 months of participation in the study
- Patients with prior history of diagnosis of heart failure with documented EF of less than 50.
Other illness
- Biopsy proven diagnosis of glomerular disease/glomerulonephritis
- Hypersensitivity to empagliflozin or finerenone
- Proven diagnosis of Polycystic Kidney Disease.
Lab values
- eGFR less than 25 mL/min/1.73 m2 by the CKD-EPI equation
Other
- If a patient is on statin, need to be on a stable dose for a month.
- Active smokers,
- Women who are pregnant, planning to become pregnant, nursing mothers, women of childbearing potential not using birth control measure
- Patients on dialysis
- At the discretion of PI to ensure health, safety, and well-being of the veteran, participation in this study may be stopped (please see withdrawal criteria)
Who the study is looking for
- Diagnosis of type 2 diabetes (HbA1C at or above 6.5%, or fasting blood glucose of more than 125 or random/ post prandial blood glucose of more than 199mg%)
- African American veterans
- Age 20-90 years
- eGFR ≥25-89 mL/min/1.73 m2 by the CKD-EPI equation)
- Albuminuria of 30 mg/g or higher
- BMI=18-39.9
- Blood pressure controlled to ≤140/90
- Ability to provide informed consent before any trial related activities are conducted.
Age in the registry: 20 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington DC Veterans Affairs Medical Center (688) Coordinator of this site? Confirm its status | Washington D.C. | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.